Abstract: The present invention relates to an adduct comprising at least one transition metal and an adduct between a sp2 carbon allotrope and a pyrrole compound. In particular, the invention relates to an adduct comprising at least one transition metal and hydrophylic adducts between a sp2 carbon allotrope and a pyrrole compound. Such adduct is preferentially used as catalytic system in a chemical reaction such as C—H activation, in particular the Hydrogen Isotope Exchange with isotopes such as deuterium and tritium.

Abstract: An in-situ method for making a conjugated diene from an allyl alcohol comprising the conversion of the allyl alcohol to an allyl carbonate, allyl ester or allyl formate with concomitant or subsequent conversion of the allyl carbonate, allyl ester or allyl formate to the conjugated diene; the products obtained by said method, and the uses of said products.

Abstract: Processes for alkylating benzene are provided. In embodiments, the process comprises combining benzene, an olefin, and a catalyst composition under conditions to react benzene with the olefin to produce an alkylbenzene, the catalyst composition comprising components selected from the group consisting of an ionic liquid, an acid, and an aromatic; an acid, a base capable of forming an ionic liquid with the acid, and an aromatic; an ionic liquid and an acid; and an acid and a base capable of forming an ionic liquid with the acid. The ionic liquid does not comprise a metal halide and the catalyst composition is free of a metal halide and the aromatic, if present in the catalyst composition, is not the benzene being alkylated.

Abstract: The present invention provides PCNHCP pincer metal complexes, which are useful as catalysts in various chemical reactions such as hydrogen isotope exchange (HIE) in C(sp3)-H and/or C(sp2)-H bond of an organic compound, e.g., a pharmaceutically active compound; hydroboration of alkynes with excellent selectivity; and alkene isomerization with high stereo- and regioselectivity.

Abstract: A composite adsorbent for separating ethylbenzene from C8 arene by an adsorption distillation contains 1-50 mass % of a xylene adsorbent and 50-99 mass % of a carrier liquid. The carrier liquid is selected from one or two of alkane, aryl-substituted alkane, decalin and alkyl-substituted decalin. The alkane is C10-C26 alkane, and the aryl-substituted alkane is C13-C16 aryl-substituted alkane. The composite adsorbent can increase the volatility of ethylbenzene relative to other C8 arenes and thus can separate a high-purity ethylbenzene from C8 arene by the adsorption distillation.

Abstract: The present disclosure relates to a method for producing a fluorinated organic compound comprises reacting a compound represented by formula (1): (wherein R1 and R2 are each independently a hydrogen atom, a halogen atom, or an organic group, or R1 and R2 optionally form a ring together with the two adjacent carbon atoms; n is 1 or 2; and wherein two R1s are optionally the same or different, two R2s are optionally the same or different, or two R?s or two R2s optionally form a ring together with their adjacent carbon atom), with (A) at least one fluorine source selected from the group consisting of hydrogen fluoride, hydrogen fluoride salts, and fluoride salts, and (B) a halogen source other than fluorine represented by the formula: R3(OX)m (wherein R3 is a hydrogen atom, a cation, or an organic group, X is a halogen atom other than a fluorine atom, and m is an integer corresponding to the valence of R3), to add fluorine and a halogen other than fluorine to the double bond or triple bond.

Abstract: There is provided a halon purification method capable of simply, safely, and efficiently removing mixed bromine molecules to obtain high purity halon. The halon purification method is a method for removing bromine molecules from crude halon containing halon and the bromine molecules, and the method includes: a contact step of bringing the crude halon into contact with an absorbing liquid containing an aqueous solution containing metal iodide to obtain a mixed liquid containing the crude halon and the absorbing liquid; and a separation step of separating the halon from the mixed liquid to obtain the halon and the absorbing liquid having absorbed the bromine molecules.

Abstract: A method of producing a catalyst comprises forming a decomposed material comprising a decomposed hydrotalcite, a decomposed hydrocalumite, or a combination of both, combining the decomposed material with a mixture to form a catalyst mixture, and heating the catalyst mixture to convert the metal salt to a metal oxide. The mixture comprises a metal salt and a chelating agent, and the resulting metal oxide combined with the decomposed material forms the catalyst.

Abstract: The present disclosure provides for organic solvent production via distillation and dehydration by: directing portions of a feed stream to a first and second distillation columns operating at a different pressures from each other, wherein the organic solvent is preferably an alcohol and more preferably ethanol; generating, in the first distillation column, a vaporous first overhead stream; directing the vaporous first overhead stream directly to a rectification system; generating, in the second distillation column, a vaporous second overhead stream; forming a condensed second overhead stream from the vaporous second overhead stream; directing, at least a portion of the condensed second overhead stream to the rectification system; generating, via the rectification system, a third overhead stream; directing at least a portion of the third overhead stream to a separation system; and generating, in the separation system, an enriched solvent stream.

Abstract: A method for producing a bisphenol or the like by using a chemical recycling method that is moderate, has a small environmental load, and can efficiently degrade a polycarbonate resin is provided. In addition, a method for producing a recycled polycarbonate resin or the like by using a useful substance such as the bisphenol or the like is provided. A method for producing a bisphenol, including degrading a polycarbonate resin in the presence of an aromatic monoalcohol, water, and a catalyst. A method for producing carbon dioxide, including recovering carbon dioxide generated by the method for producing a bisphenol. A method for producing a carbonic acid diester by using the carbon dioxide. A method for producing a recycled polycarbonate resin by using the bisphenol and/or the carbonic acid diester.

Abstract: Provided herein are methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, for example, in the treatment of a mental health disorder or chronic inflammatory disease.

Abstract: The invention relates to a process for the conversion of furfuryl alcohol into a levulinate ester comprising contacting furfuryl alcohol; an alcohol, or a mixture thereof; and a homogeneous catalyst at a first reaction temperature in the range of from 125 to 180° C. to form a reaction mixture; and forming the levulinate ester in the reaction mixture, characterised in that the first homogeneous catalyst is a sulfonic acid catalyst.

Abstract: The present application relates to an organic compound, and an electronic component and electronic device having the same, and belongs to the technical field of organic electroluminescence. The organic compound of the present application has a structure shown in formula 1. When used in an electronic component, the organic compound of the present application can significantly improve the performance of the electronic component.

Abstract: Described herein are crystalline forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-in-dene-2-carboxylic acid and methods of making the same. Such forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with an EDG-2 receptor antagonist compound.

Abstract: The present invention relates to a process for the preparation of a key intermediate and other intermediates useful for the synthesis of Siponimod, a drug used for the treatment of multiple sclerosis. Object of the invention are also said novel intermediates.

Abstract: The present invention relates to the use of strobilurin type compounds of formula (I) and the N-oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, and to seeds coated with at least one such compound.

Abstract: A process for the production of biuret from urea wherein: a urea aqueous solution (24) withdrawn from the recovery section of a urea plant is processed to remove water and obtain a concentrated urea melt (25); said urea melt is processed under biuret-forming conditions to decompose urea into biuret and ammonia and obtain a high-biuret urea melt (26); said high-biuret urea melt (26) is diluted with water or with an aqueous stream obtaining a solution (28); the solution (28) is subject to crystallization and precipitation of a solid phase containing biuret which is separated from the aqueous phase.

Abstract: Methods of producing N,N-branched sulfamoyl fluoride compounds of the formula F-S(O)2-NR2 by contacting bismuth trifluoride with an N,N-branched sulfamoyl nonfluorohalide compound of the formula X-SO2NR2, wherein X=chlorine (Cl), bromine (Br), or iodine (I), and each R is, independently, a linear or branched alkyl, fluoroalkyl, alkenyl, fluoroalkenyl, alkynyl, or fluoroalkynyl with 1 to 12 carbon atoms, to fluorinate the N,N-branched sulfamoyl nonfluorohalide compound. This is a non-aqueous method, the purity of product is very high, and the desired product can be isolated in quantitative yield. The N,N-branched sulfamoyl fluoride compounds so produced are useful in various applications including as electrolyte solvents and additives in electrochemical devices, such as lithium batteries and capacitors, and in biological fields, among others.

Abstract: Alkane multi-sulfonic acids and salts thereof are provided. In embodiments, an alkane multi-sulfonic acid or salt thereof comprises an alkyl group and at least two sulfonic acid groups, the alkane multi-sulfonic acid having a total number of carbon atoms of from 2 to 9, wherein the alkane multi-sulfonic acid does not comprise a halogen.

Abstract: Haloalkane sulfonic acids and salts thereof are provided. In embodiments, a haloalkane sulfonic acid or salt thereof comprises an alkyl group, at least one sulfonic acid group, and one or more halogens selected from Cl, Br, I, and F, the haloalkane sulfonic acid having a total number of carbon atoms of from 2 to 9, and wherein if at least one F atom is present, the haloalkane sulfonic acid comprises at least one other halogen selected from Cl, Br, and I. Methods of making and using the haloalkane sulfonic acids/salts are also provided.

Abstract: A polythiol composition according to exemplary examples includes a tetrafunctional polythiol compound, and a sub-polythiol compound including a compound represented by C13H28S9 and a compound represented by C15H32S10. A ratio of the sub-polythiol compound measured through a high performance liquid chromatography (HPLC) analysis graph is 1% to 5%. By adjusting the content of the sub-polythiol compound, it is possible to manufacture an optical product having excellent transmittance and optical properties.

Abstract: The present invention relates to crystalline complexes of sulforaphane and alpha-cyclodextrin; pharmaceutical compositions comprising the complexes; methods for their manufacture; and the use of said complexes as a medicament.

Abstract: The present disclosure provides for compositions of, synthetic methods of, and methods for use of dihydrofolate synthase (DHFS) inhibiting agents.

Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

Abstract: The present invention provides a production method of a 3-cyanopyrrole compound possibly useful as an intermediate for pharmaceutical products. A production method of compound (II) including subjecting compound (I) to a reduction reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst. A production method of compound (III) including subjecting compound (I) to a reduction reaction followed by a cyclization reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst.

Abstract: The disclosure provides a dipyrrolidine-1-one compound represented by formula 1; R is hydrogen, C1-C5 alkyl, or benzyl; R1 is selected from thiophenyl, phenylsulfinyl, phenylsulfonyl, p-toluene sulfide, p-tosylsulfinyl, and tosyl; and R2 is selected from methyl, alkoxycarbonyl, formyl, acetoxymethyl, carboxyl, and hydrogen. The compound is prepared by a compound represented by formula 2 and a compound represented by formula 3 through a condensation reaction.

Abstract: A pyrrolinone compound represented by formula 1. R1 is selected from one of C1-C5 alkoxy, benzyloxy, C1-C5 alkyl, or a phenyl group; R2, R3 at each occurrence independently represent hydrogen, C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkylthio, C1-C5 alkane sulfinyl, C1-C5 alkane sulfonyl, a substituted phenyl, a substituted phenoxy, a substituted phenylthio, a substituted phenylene sulfinyl, or a substituted benzene sulfonyl; and n1, n2 at each occurrence independently are an integer from 1 to 5.

Abstract: The present disclosure is directed to compounds, compositions, formulations and methods of use thereof in the treatment and prevention of ocular conditions including cataract and presbyopia.

Abstract: A compound is represented by a formula (1) below, in which k is an integer of 0 or more, m is an integer of 1 or more, n is an integer of 2 or more. L is a substituted or unsubstituted aromatic hydrocarbon ring having 6 to 30 ring carbon atoms, CN is a cyano group, and D1 and D2 are each independently represented by one of a formula (2), a formula (3) and formula (3x) below, D1 and D2 being optionally mutually the same or different.

Abstract: The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

Abstract: A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) represented by the formula (1): The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form A, thereby to obtain a drug substance excellent in stability.

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.

Abstract: The present invention provides processes and key intermediates for the synthesis of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro-propane-2-yl)-1H-pyrazole-4-carboxamide:

Abstract: The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

Abstract: The invention relates to new olaparib oxalic acid cocrystals. The olaparib oxalic acid cocrystals vary in ratio from 1:1 to 2:3 olaparib: oxalic acid. In particular, the invention relates to a 2:3 olaparib oxalic acid cocrystal, a 1:1 olaparib oxalic acid cocrystal, and a 2:1 olaparib oxalic acid cocrystal. The invention also relates to pharmaceutical compositions containing an olaparib oxalic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib oxalic acid cocrystals of the invention may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP). These include cancer, fibrosis, inflammatory conditions (e.g. asthma, colitis, arthritis), neurological diseases (e.g. neurodegeneration, neurotrauma, stroke), cardiovascular conditions, ophthalmic degenerative diseases, vascular diseases (e.g. diabetic complications, atherosclerosis), and various forms of critical illness (e.g. septic shock, ALI, acute liver failure).

Abstract: Provided are a salt of an arylaminoquinazoline-containing compound as shown in formula 2, a solvate or hydrate thereof, a preparation method therefor and the use thereof. The prepared salt has good crystallinity, and compared to a compound in a free form, the water solubility is significantly improved, and preferably, the salt form and crystal form can stably exist. Therefore, compared to a compound in a free form or other salts, the salt has better druggability.

Abstract: The invention provides compounds formula (I) and salts thereof: wherein R1-R2 have any of the values defined in the specification. The compounds are useful for treating conditions including Alzheimer? s disease, Parkinson’s disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia. The compounds are also useful to lower IL-4, IL-5, or IL-15 levels in an animal.

Abstract: Novel ionizable lipids, compositions, and methods of using the novel ionizable lipids and compositions are disclosed. Lipid nanoparticle compositions include a novel ionizable lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticle compositions further including biologically active agents such as mRNA or DNA are useful in the delivery of biologically active agents to mammalian cells or organs.

Abstract: An organic compound represented by [1], satisfying (i) and (ii), and represented by [2-1] or [2-2]. A-(B)m??[1] (i) T1 of the unit A<T1 of the unit B, and (ii) HOMO-LUMO orbitals responsible for T1 transition are present in the unit A, wherein R1 is selected from alkyl groups and the like, m denotes an integer of 1 or more and 5 or less, and n denotes an integer of 0 or more and 4 or less, the unit B is a fused ring with a partial structure represented by the general formula [3-1] or [3-2] or the like and is bonded to the unit A via a carbon atom, wherein X is selected from an oxygen atom, a sulfur atom, and the like, and the rings C to E independently denote a single ring and may have a deuterium atom or an alkyl group.

Abstract: The present invention provides compounds as PPAR agonists and their application, involving a new class of peroxisome proliferator-activated receptor (PPAR) gamma receptor agonist, which can inhibit the production of mitochondrial reactive oxygen species, and most of which can readily cross the blood-brain barrier. The present invention also includes pharmaceutical uses of the compounds.

Abstract: The present invention relates to a process for the preparation 2-chloro-1-(2-chlorothiazol-5-yl)ethanone.

Abstract: A compound of formula (I): Ar1??(I) Ar1 is a fused aromatic or heteroaromatic group substituted with at least one group of formula (II): R2 in each occurrence is H or a substituent, Y is O, S or NR9 wherein R9 is H or a substituent; --- is a bond to a ring carbon atom of Ar1; and, for each group of formula (II), a ring carbon atom of Ar1 adjacent to a ring carbon atom bound to the group of formula (II) is substituted with a group of formula —XR1 wherein X is O, S or NR3 wherein R3 is H or C1-12 alkyl and R1 is a photocleavable group. Data may be written to a recording medium containing a compound of formula (I) by exposing it to a wavelength for photolysis of the photocleavable group.

Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.

Abstract: Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of providing a crude acesulfame potassium composition comprising acesulfame potassium and acetoacetamide, concentrating the crude acesulfame potassium composition to form a water stream and an intermediate acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide, and separating the intermediate acesulfame potassium composition to form the finished acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide. The concentrating step is conducted at a temperature below 90° C. and the separating step is conducted at a temperature at or below 35° C.

Abstract: A process for producing acesulfame potassium, the process comprising the steps of providing a cyclizing agent composition comprising a cyclizing agent and a solvent and having an initial temperature, cooling the cyclizing agent composition to form a cooled cyclizing agent composition having a cooled temperature less than 35° C., reacting an acetoacetamide salt with the cyclizing agent in the cooled cyclizing agent composition to form a cyclic sulfur trioxide adduct composition comprising cyclic sulfur trioxide adduct; and, forming from the cyclic sulfur trioxide adduct in the cyclic sulfur trioxide adduct composition the finished acesulfame potassium composition comprising non-chlorinated acesulfame potassium and less than 39 wppm 5-chloro-acesulfame potassium. The cooled temperature is at least 2° C. less than the initial temperature.

Abstract: Improved processes for producing high purity acesulfame potassium. In one embodiment, the process comprises the steps of contacting a solvent, e.g., dichloromethane, and a cyclizing agent, e.g., sulfur trioxide, to form a cyclizing agent composition and reacting an acetoacetamide salt with the cyclizing agent in the composition to form a cyclic sulfur trioxide adduct. The contact time is less than 60 minutes. The process also comprises forming from the cyclic sulfur trioxide adduct composition a finished acesulfame potassium composition comprising non-chlorinated, e.g., non-chlorinated, acesulfame potassium and less than 35 wppm 5-halo acesulfame potassium, preferably less than 5 wppm.

Abstract: A method for preparing compound 1 and compound 2 having a structure as shown below, the method includes the following steps: 1) subjecting 2,3-dihydrobenzofuran-7-amine as a raw material to a selective-dibromination with a brominating reagent to obtain 4,6-dibromo-2,3-dihydrobenzofuran-7-amine; 2) subjecting 4,6-dibromo-2,3-dihydrobenzofuran-7-amine obtained in the step 1) to Sandmeyer reaction for chlorination to obtain 4,6-dibromo-7-chloro-2,3-dihydrobenzofuran; 3-1) selectively debrominating from 4,6-dibromo-7-chloro-2,3-dihydrobenzofuran obtained in the step 2) using a strong base, and then adding a formylation reagent to obtain compound 1; 3-2) selectively debrominating from 4,6-dibromo-7-chloro-2,3-dihydrobenzofuran obtained in the step 2) using a strong base, and then reacting with 4-cyclopropyl benzaldehyde to obtain compound 2.

Abstract: The present application discloses a tetrastyrene-based compound, an application thereof, and an electronic device using the same. The tetrastyrene-based compound has a general structural formula as shown in the following Formula 1: The tetrastyrene-based compound includes an aromatic amine and a rigid tetrastyrene structure, wherein the aromatic amine can effectively improve the hole injection and transport performance, and the rigid tetrastyrene structure is conducive to the formation of evaporation materials of melting type.

Abstract: A class of xanthine oxidase (XO) inhibitors, and application thereof in the preparation of drugs for treating XO-related diseases. Specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.